CAS 340021-17-2

Tonapofylline

Description:

Tonapofylline, identified by its CAS number 340021-17-2, is a chemical compound that belongs to the class of phosphodiesterase inhibitors. It is primarily studied for its potential therapeutic applications, particularly in the context of cardiovascular diseases and conditions associated with impaired blood flow. The compound exhibits properties that may enhance vasodilation and improve endothelial function, making it of interest in pharmacological research. Tonapofylline's mechanism of action involves the modulation of cyclic nucleotide levels, which play a crucial role in various cellular processes. While specific physical and chemical properties such as solubility, melting point, and stability may vary, the compound is typically characterized by its ability to interact with biological systems effectively. Ongoing research continues to explore its efficacy, safety, and potential side effects, contributing to a better understanding of its role in medical applications. As with any pharmaceutical compound, thorough investigation and clinical trials are essential to establish its therapeutic potential and safety profile.

Formula: C₂₂H₃₂N₄O₄

InChI: InChI=1S/C22H32N4O4/c1-3-13-25-17-16(18(29)26(14-4-2)20(25)30)23-19(24-17)22-10-7-21(8-11-22,9-12-22)6-5-15(27)28/h3-14H2,1-2H3,(H,23,24)(H,27,28)

InChI key: InChIKey=ZWTVVWUOTJRXKM-UHFFFAOYSA-N

SMILES: C(CC(O)=O)C12CCC(CC1)(CC2)C3=NC4=C(N3)C(=O)N(CCC)C(=O)N4CCC

Synonyms:

• Tonapofylline
• 4-(2,3,6,7-Tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)bicyclo[2.2.2]octane-1-propanoic acid
• BG 9928
• Bicyclo[2.2.2]octane-1-propanoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-

Tonapofylline

CAS: 340021-17-2

Tonapofylline

Purity: ≥98%

Molecular weight: 416.51g/mol

Ref: 54-BUP09294

Tonapofylline

CAS: 340021-17-2

Tonapofylline is a pharmaceutical preparation that is used to treat glomerular filtration rate problems and hepatic impairment. It is also used for the treatment of pulmonary edema caused by congestive heart failure, myocardial infarction, or cirrhosis. Tonapofylline inhibits the adenosine receptors in the lungs, which blocks the inhibitory effects of adenosine on the airways. This improves lung function and reduces pulmonary edema. Tonapofylline has also been shown to reduce levels of urea nitrogen and creatinine in patients with cirrhosis and cancer. Tonapofylline may also be used for cancer prevention because it lowers the risk of myocardial infarcts in patients with coronary artery disease or congestive heart failure.

Formula: C₂₂H₃₂N₄O₄

Purity: Min. 95%

Molecular weight: 416.5 g/mol

Ref: 3D-QNA02117

Tonapofylline

CAS: 340021-17-2

Tonapofylline, orally active, selectively blocks A1 adenosine receptor (Ki: 7.4 nM), used in heart failure research.

Formula: C₂₂H₃₂N₄O₄

Purity: 98.57%

Color and Shape: Solid

Molecular weight: 416.51

Ref: TM-T17117